CPHI & PMEC India 2025 ignites pharma innovation and partnerships
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Adverse events were consistent with valbenazine’s established safety profile
Subscribe To Our Newsletter & Stay Updated